{"id":1846,"date":"2013-03-01T12:02:00","date_gmt":"2013-03-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/gliptine-zur-behandlung-von-patienten-mit-diabetes-mellitus-typ-2"},"modified":"2013-03-01T12:02:00","modified_gmt":"2013-03-01T11:02:00","slug":"gliptine-zur-behandlung-von-patienten-mit-diabetes-mellitus-typ-2","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/gliptine-zur-behandlung-von-patienten-mit-diabetes-mellitus-typ-2","title":{"rendered":"Gliptine zur Behandlung von Patienten mit Diabetes mellitus Typ 2"},"content":{"rendered":"<p>Die Gliptine geh\u00f6ren zu den Dipeptidyl-Peptidase-4(DPP-4)-Antagonisten (Inkretinmimetika). Sie hemmen die Inaktivierung der Inkretinhormone GLP-1 (Glucagon-like peptide-1) und GDIP (Glucose-dependent insulinotropic peptide) und erleichtern dadurch die Blutzuckereinstellung bei Patienten mit Diabetes mellitus Typ 2. Als erste Substanz aus dieser Gruppe wurde im Jahr 2006 (in Europa 2007) Sitagliptin (Januvia\u00ae) zugelassen auf der Basis randomisierter kontrollierter Studien, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Gliptine geh\u00f6ren zu den Dipeptidyl-Peptidase-4(DPP-4)-Antagonisten (Inkretinmimetika). Sie hemmen die Inaktivierung der Inkretinhormone GLP-1 (Glucagon-like peptide-1) und GDIP (Glucose-dependent insulinotropic peptide) und erleichtern dadurch die Blutzuckereinstellung bei Patienten mit Diabetes mellitus Typ 2. Als erste Substanz aus dieser Gruppe wurde im Jahr 2006 (in Europa 2007) Sitagliptin (Januvia\u00ae) zugelassen auf der Basis randomisierter kontrollierter Studien, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[4081,4079,155,4080,1310,1309,2291,1307,1308,1441,4078,1442],"class_list":["post-1846","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alogliptin","tag-carolina-studie","tag-diabetes-mellitus-typ-2","tag-examine-studie","tag-gliptine","tag-inkretinmimetika","tag-linagliptin","tag-savor-timi-53-studie","tag-saxagliptin","tag-sitagliptin","tag-tecos-studie","tag-vildagliptin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1846"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1846\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}